EOFlow launches world’s 2nd wearable insulin pump

EOFlow, a medical gadget developer, stated Monday that it has launched the world’s second wearable insulin pump, EOPatch.

“The insulin remedy has been exhibiting speedy developments past insulin pen and glucose meters and heading towards a one-in-system combining insulin pump, steady glucose monitoring, and insulin patch,” Professor Park Cheol-young of the Division of Endocrinology at Kangbuk Samsung Hospital stated at a information convention.  

Park stated that it’s essential to implement an built-in administration system able to decreasing hyperglycemia and hypoglycemia by making use of algorithms to observe blood glucose stage, insulin dosage, and drugs historical past to enhance blood sugar controls.

Park emphasised the necessity to develop an answer that reduces the variety of administration and improves the comfort of use by enhancing the mounted injection time.

EOPatch is a disposable insulin pump permitting improved lesion administration by injecting insulin into the physique by attaching it to the stomach. It repeatedly delivers insulin to diabetic sufferers for his or her blood sugar administration.

The corporate has improved the convenience of use by eradicating the tube from the prevailing insulin pumps. The gadget is waterproof with reduces dimension and weight and permits weekly substitute by customers.

EOFlow designed the wearable patch controllable by the Superior Diabetes Supervisor (ADM) and EOBridge, analyzing statistical diabetes information. EOBridge gives customers’ blood glucose stage and injection historical past via an app or web site, and the information might be shared with guardians and healthcare suppliers.

Commenting on the gadget’s doable malfunctioning, EOFlow CEO Kim Jae-jin defined that the corporate has examined security with hundreds of its product samples and reported no issues.

He identified that the EOPatch instantly alarms customers when it malfunctions or reads glucose meter incorrectly and stops functioning.

“We’ve got signed an settlement with Menarini to produce EOPatch to the European market, and in addition contacted with numerous corporations for its U.S. provide,” CEO Kim stated. “For the subsequent scientific trials to be carried out in different nations, we’ve got optimistic outlooks for recruiting.”

Kim added that the corporate envisions brilliant development prospects for its product sooner or later, as tens of tens of millions of sufferers use multiple-dose insulin (MDI) injections, who’ve begun switching to wearable gadgets.

EOFlow is stepping up its growth efforts to commercialize wearable synthetic pancreas in 2022 and all-in-one wearable synthetic pancreas in 2023.